Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Tomomi Yamamoto

TitleSr Research Associate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-OB/GYN RS GENERAL OPS
Phone303/724-0442

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bapat J, Yamamoto TM, Woodruff ER, Qamar L, Mikeska RG, Aird KM, Watson ZL, Brubaker LW, Bitler BG. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR. Cancer Gene Ther. 2023 Nov 29. PMID: 38030811.
      View in: PubMed
    2. Bitler BG, Bailey CA, Yamamoto TM, McMellen A, Kim H, Watson ZL. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma. Mol Carcinog. 2023 11; 62(11):1717-1730. PMID: 37493106.
      View in: PubMed
    3. Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023 Apr-May; 27(4-5):361-371. PMID: 37243607.
      View in: PubMed
    4. Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, Jeong AD, Guntupalli SR, Behbakht K, Gbaja V, Arnoult N, Chuong EB, Bitler BG. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models. bioRxiv. 2023 Feb 23. PMID: 36865165.
      View in: PubMed
    5. McMellen A, Yamamoto TM, Qamar L, Sanders BE, Nguyen LL, Ortiz Chavez D, Bapat J, Berning A, Post MD, Johnson J, Behbakht K, Nurmemmedov E, Chuong EB, Bitler BG. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Mol Cancer Res. 2023 01 03; 21(1):3-13. PMID: 36149636.
      View in: PubMed
    6. Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, Lee JM, Nair JR. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. Oncogene. 2022 11; 41(46):5020-5031. PMID: 36224341.
      View in: PubMed
    7. Sanders BE, Yamamoto TM, McMellen A, Woodruff ER, Berning A, Post MD, Bitler BG. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma. Mol Cancer Ther. 2022 08 02; 21(8):1285-1295. PMID: 35587258.
      View in: PubMed
    8. Yamamoto TM, Webb PG, Davis DM, Baumgartner HK, Woodruff ER, Guntupalli SR, Neville M, Behbakht K, Bitler BG. Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Mol Cancer Ther. 2022 04 01; 21(4):647-657. PMID: 35373300.
      View in: PubMed
    9. Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 12 01; 26(23):6362-6373. PMID: 32928797.
      View in: PubMed
    10. Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 07; 18(7):1088-1098. PMID: 32198139.
      View in: PubMed
    11. Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165. PMID: 31775874.
      View in: PubMed
    12. Rao DM, Shackleford MT, Bordeaux EK, Sottnik JL, Ferguson RL, Yamamoto TM, Wellberg EA, Bitler BG, Sikora MJ. Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine O-acyltransferase or Wnt secretion. J Biol Chem. 2019 12 27; 294(52):19950-19966. PMID: 31740580.
      View in: PubMed
    13. Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. Mol Cancer Ther. 2020 02; 19(2):602-613. PMID: 31575654.
      View in: PubMed
    14. Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Sawyer BT, Sullivan KD, Khanal S, Joshi M, Ferchaud-Roucher V, Smith H, Vanderlinden LA, Brubaker SW, Caino CM, Kim H, Espinosa JM, Richer JK, Bitler BG. Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. iScience. 2019 Sep 27; 19:474-491. PMID: 31437751.
      View in: PubMed
    15. Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 10; 58(10):1770-1782. PMID: 31219654.
      View in: PubMed
    16. Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018 Nov 26; 7(11):92. PMID: 30478317.
      View in: PubMed
    17. Gillen AE, Brechbuhl HM, Yamamoto TM, Kline E, Pillai MM, Hesselberth JR, Kabos P. Alternative Polyadenylation of PRELID1 Regulates Mitochondrial ROS Signaling and Cancer Outcomes. Mol Cancer Res. 2017 12; 15(12):1741-1751. PMID: 28912168.
      View in: PubMed
    18. Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 01; 23(7):1710-1721. PMID: 27702820.
      View in: PubMed
    19. Gillen AE, Yamamoto TM, Kline E, Hesselberth JR, Kabos P. Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics. 2016 05 05; 17:338. PMID: 27150721.
      View in: PubMed
    20. Pillai MM, Gillen AE, Yamamoto TM, Kline E, Brown J, Flory K, Hesselberth JR, Kabos P. HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer. Breast Cancer Res Treat. 2014 Jul; 146(1):85-97. PMID: 24906430.
      View in: PubMed
    21. Yamamoto TM, Wang L, Fisher LA, Eckerdt FD, Peng A. Regulation of Greatwall kinase by protein stabilization and nuclear localization. Cell Cycle. 2014; 13(22):3565-75. PMID: 25483093.
      View in: PubMed
    22. Yamamoto TM, Cook JM, Kotter CV, Khat T, Silva KD, Ferreyros M, Holt JW, Knight JD, Charlesworth A. Zar1 represses translation in Xenopus oocytes and binds to the TCS in maternal mRNAs with different characteristics than Zar2. Biochim Biophys Acta. 2013 Oct; 1829(10):1034-46. PMID: 23827238.
      View in: PubMed
    23. Le TT, Mawatari K, Maetani M, Yamamoto T, Hayashida S, Iba H, Aihara M, Hirata A, Shimohata T, Uebanso T, Takahashi A. VP2118 has major roles in Vibrio parahaemolyticus response to oxidative stress. Biochim Biophys Acta. 2012 Oct; 1820(10):1686-92. PMID: 22771831.
      View in: PubMed
    24. Charlesworth A, Yamamoto TM, Cook JM, Silva KD, Kotter CV, Carter GS, Holt JW, Lavender HF, MacNicol AM, Ying Wang Y, Wilczynska A. Xenopus laevis zygote arrest 2 (zar2) encodes a zinc finger RNA-binding protein that binds to the translational control sequence in the maternal Wee1 mRNA and regulates translation. Dev Biol. 2012 Sep 15; 369(2):177-90. PMID: 22732570.
      View in: PubMed
    25. Blake-Hodek KA, Williams BC, Zhao Y, Castilho PV, Chen W, Mao Y, Yamamoto TM, Goldberg ML. Determinants for activation of the atypical AGC kinase Greatwall during M phase entry. Mol Cell Biol. 2012 Apr; 32(8):1337-53. PMID: 22354989.
      View in: PubMed
    26. Yamamoto TM, Blake-Hodek K, Williams BC, Lewellyn AL, Goldberg ML, Maller JL. Regulation of Greatwall kinase during Xenopus oocyte maturation. Mol Biol Cell. 2011 Jul 01; 22(13):2157-64. PMID: 21551066.
      View in: PubMed
    27. Eckerdt F, Yamamoto TM, Lewellyn AL, Maller JL. Identification of a polo-like kinase 4-dependent pathway for de novo centriole formation. Curr Biol. 2011 Mar 08; 21(5):428-32. PMID: 21353560.
      View in: PubMed
    28. Nagatomo K, Ishii H, Yamamoto T, Nakajo K, Kubo Y. The Met268Pro mutation of mouse TRPA1 changes the effect of caffeine from activation to suppression. Biophys J. 2010 Dec 01; 99(11):3609-18. PMID: 21112285.
      View in: PubMed
    29. Peng A, Yamamoto TM, Goldberg ML, Maller JL. A novel role for greatwall kinase in recovery from DNA damage. Cell Cycle. 2010 Nov 01; 9(21):4364-9. PMID: 20980823.
      View in: PubMed
    30. Yamamoto TM, Lewellyn AL, Maller JL. Regulation of the Aurora B chromosome passenger protein complex during oocyte maturation in Xenopus laevis. Mol Cell Biol. 2008 Jun; 28(12):4196-203. PMID: 18378691.
      View in: PubMed
    31. Ohsumi K, Yamamoto TM, Iwabuchi M. Oocyte extracts for the study of meiotic M-M transition. Methods Mol Biol. 2006; 322:445-58. PMID: 16739743.
      View in: PubMed
    32. Yamamoto TM, Iwabuchi M, Ohsumi K, Kishimoto T. APC/C-Cdc20-mediated degradation of cyclin B participates in CSF arrest in unfertilized Xenopus eggs. Dev Biol. 2005 Mar 15; 279(2):345-55. PMID: 15733663.
      View in: PubMed
    33. Ohsumi K, Koyanagi A, Yamamoto TM, Gotoh T, Kishimoto T. Emi1-mediated M-phase arrest in Xenopus eggs is distinct from cytostatic factor arrest. Proc Natl Acad Sci U S A. 2004 Aug 24; 101(34):12531-6. PMID: 15314241.
      View in: PubMed
    34. Ebihara S, Yamamoto T, Obata K, Yanagawa Y. Gene structure and alternative splicing of the mouse glycine transporter type-2. Biochem Biophys Res Commun. 2004 May 07; 317(3):857-64. PMID: 15081419.
      View in: PubMed
    Yamamoto's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)